Pyrosequencing AB
This article was originally published in The Gray Sheet
Executive Summary
German Armed Forces purchases bench-top PSQ 96 system for typing and validation of bacteria and viruses used to produce biological weapons, such as anthrax and smallpox. Additional European defense organizations have expressed interest in the system, the Swedish firm announced Nov. 29. The single nucleotide polymorphism technology for identification and quantification of short DNA sequences, which offers results in as little as 10 minutes and costs about $90,000, is currently being used for research purposes and environmental testing. In the future, Pyrosequencing expects to partner with labs to develop clinical assays for a wide range of indications...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.